nimacimab — Topline data
Q4 2026
We expect to report topline data from the expansion study in the fourth quarter of 2026.Source filing
SKYE biotech catalysts & pipeline
SKYE BIOSCIENCE INC · Data as of 2026-09-08
Upcoming catalysts
Discoidin Domain Receptor inhibitor — IND submission
2027
IND submission for a DDR inhibitor is expected in 2027.Source filing
RXC008 — Topline data
H2 2028
Financings expected to fund operations through RXC008 Phase 2 clinical trial – topline data expected H2 2028Source filing